Abstract

The pathogenesis of pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. S100 calcium-binding protein A6 (S100A6) has been associated with PDAC; however, the effect of S100A6 on PDAC migration and invasion has not yet been explored. In this study, Panc-1 cells were transfected with a plasmid to induce overexpression of S100A6, and β-catenin was knocked down using a specific short hairpin RNA (shRNA). The wound-healing and Transwell assays demonstrated that S100A6 promoted PDAC cell migration and invasion. Furthermore, β-catenin shRNA inhibited the migration and invasion of PDAC cells. We confirmed that S100A6 induces PDAC cell migration and invasion via activation of β-catenin in vitro. Assessment of mRNA and protein levels revealed that S100A6 induces increased expression of β-catenin, N-cadherin and vimentin, and decreased expression of E-cadherin in PDAC cells. β-catenin shRNA also altered the expression of epithelial-mesenchymal transition (EMT)-related markers in PDAC cells. Specifically, expression of E-cadherin was increased, whereas expression of N-cadherin and vimentin was decreased. Finally, we demonstrated that S100A6 alters the expression of EMT-related markers via β-catenin activation. In conclusion, S100A6 induces EMT and promotes cell migration and invasion in a β-catenin-dependent manner. S100A6 may therefore represent a novel potential therapeutic target for the treatment of pancreatic cancer.

Highlights

  • Pancreatic ductal adenocarcinoma (PDAC) is a serious global health problem

  • Real-time RT-PCR was used to verify that the S100 calcium-binding protein A6 (S100A6) overexpression plasmid increased the mRNA levels of S100A6 in Panc-1 cells

  • We detected a significant increase in the level of S100A6 mRNA in S100A6-overexpressing cells, compared to control cells (p < 0.001) (S1 Fig.)

Read more

Summary

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a serious global health problem. It is the fourth most common cause of cancer-related death in the United States, with a 5-year overall relative survival rate of 6%[1]. In China, The median survival time of PDAC patients is 7.8 months, with 30.0% of patients undergoing curative intent operations, and only 9.8% of patients receiving comprehensive treatment[2]. PDAC remains extremely resistant to currently available radiotherapy and chemotherapy regimens[3]. One contributor to PLOS ONE | DOI:10.1371/journal.pone.0121319. One contributor to PLOS ONE | DOI:10.1371/journal.pone.0121319 March 23, 2015

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call